Vytorin Study Causes Media Stir, but Are the Concerns Justified?
Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.
Merck and Schering-Plough's announcement last week that Vytorin did not show any evidence of reducing fatty plaque buildup in veins and arteries stirred up a lot of complaints from industry pundits who felt that the public was misled by pharma.
There's only one hitch: The two pharma companies never stated that the drug, a cholesterol-lowering combination of Zocor and Zetia, had an effect on plaque.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
